Secukinumab Improved HRQOL, Symptoms in Pediatric Generalized Pustular Psoriasis

May 20th 2022, 5:30pm


Over 48 weeks, secukinumab was shown to be effective and safe in a small study of 18 children with generalized pustular psoriasis in China.

Researchers Suggest Cons of Cannabinoids in Rheumatology Outweigh Pros

May 17th 2022, 3:25pm


While current data on medical cannabinoids in rheumatology is limited, findings suggest that adverse events (AEs) and drug interactions outweigh the benefits.

Machine Learning–Based Predictors for RA Relapse Evaluated

May 13th 2022, 7:25pm


Researchers found that the extreme gradient boosting (XGBoost) predictor could more accurately predict rheumatoid arthritis (RA) relapse than logistic regression and random forest.

Age, Sex, Socioeconomic Status Play a Role in Likelihood of Consistent RA Treatment, Study Says

May 10th 2022, 5:55pm


Male sex, older age, lower socioeconomic status, higher comorbidity score, and having an older or male rheumatologist were associated with the reduced likelihood of continuing with rheumatoid arthritis (RA) treatment.

Men With ACPA-Negative Early RA More Likely to Achieve Remission Than Women, Study Suggests

May 6th 2022, 6:00pm


According to the authors, sex-based differences may be a cause of higher rheumatoid arthritis (RA) disease activity.

Patient-Physician Discordance Associated With Lack of RA Clinical Remission

May 3rd 2022, 8:03pm


Among patients with rheumatoid arthritis (RA) in clinical remission, patient-physician discordance when assessing disease activity may be associated with the inability to achieve remission.

High Prevalence of Metabolic Syndrome in Patients With RA Warrants Early Identification Measures

April 26th 2022, 12:20pm


A meta-analysis found that a third of patients with rheumatoid arthritis (RA) in a sample had metabolic syndrome, which can double the risk of cardiovascular outcomes in this population.

Secukinumab 300 mg Dose Improved Symptoms of Psoriatic Arthritis, Study Finds

April 23rd 2022, 5:47pm


Results from the CHOICE study suggest that both a 150 mg and 300 mg dose of secukinumab improved symptoms of psoriatic arthritis (PsA) in biologic-naïve patients, with higher response rates for the 300 mg dose.

Early Immunosuppressive Therapy Linked to Better Outcomes for RA-Associated Peripheral Ulcerative Keratitis

April 19th 2022, 7:45pm


Patients who received early immunosuppressive therapy for their rheumatoid arthritis (RA)–associated peripheral ulcerative keratitis experienced earlier inflammatory control, fewer recurrences, and better visual outcomes.

Study Finds Time-Varying Association Between RA Disease Activity and CVD Risk

April 16th 2022, 5:14pm


The association between higher disease activity risk of cardiovascular (CV) events was strongest during the first 6 months of follow-up, the study found.